I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| CD8-positive, alpha-beta T cell | 7 studies | 25% ± 10% | |
| epithelial cell | 6 studies | 27% ± 8% | |
| natural killer cell | 6 studies | 24% ± 7% | |
| type II pneumocyte | 5 studies | 25% ± 13% | |
| CD4-positive, alpha-beta T cell | 5 studies | 29% ± 10% | |
| plasmablast | 4 studies | 37% ± 23% | |
| classical monocyte | 4 studies | 24% ± 7% | |
| abnormal cell | 4 studies | 17% ± 2% | |
| B cell | 3 studies | 21% ± 4% | |
| conventional dendritic cell | 3 studies | 29% ± 10% | |
| hematopoietic precursor cell | 3 studies | 23% ± 4% | |
| non-classical monocyte | 3 studies | 27% ± 6% | |
| monocyte | 3 studies | 20% ± 6% | |
| endothelial cell | 3 studies | 20% ± 5% | |
| pro-B cell | 3 studies | 22% ± 3% | |
| fibroblast | 3 studies | 24% ± 5% | |
| ciliated cell | 3 studies | 29% ± 10% | |
| dendritic cell | 3 studies | 29% ± 7% | |
| transit amplifying cell | 3 studies | 31% ± 6% | |
| T cell | 3 studies | 27% ± 3% |
